Schott Pharma

Investor Presentation • Dec 11, 2025

Results presentation FY 2025

Andreas Reisse, CEO | Reinhard Mayer, CFO

The fiscal year 2025 runs from October 2024 to September 2025.

© SCHOTT Pharma

Disclaimer

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma's disclosures, in particular in the chapter "Risks" in SCHOTT Pharma's annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward-looking statements.

These statements may be identified by words such as "expect," "want," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.

Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma's net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further information regarding the alternative financial metrics used

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

at SCHOTT Pharma can be found on our web site (https://www.schott-pharma.com/investor-relations).

Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.

Strategy and Business Update

Andreas Reisse, CEO

FY 2025 track record: Successful strategy execution, preparation for future growth

Full-year targets met with continued revenue growth at high profitability

Successful high-value solutions (HVS) expansion - revenue share increased to 57%

Expanded capacities to ensure growth and competitiveness in global production network

Sustained position as innovation leader, delivering product launches from pipeline

Management succession settled: Appointment of incoming CEO and new CFO

Experience and fresh perspectives united in a strong new leadership team

Christian Mias appointed as CEO of SCHOTT Pharma as of May 1, 2026

Reinhard Mayer took over SCHOTT Pharma's CFO role on August 1, 2025

Delivering on full year revenue and profitability targets

Specified FY 2025 guidance FY 2025 actuals

Revenue growth¹

around

6% 5.8%

around

28% 28.4%

¹At constant currencies

6 © SCHOTT Pharma

Ideally positioned to leverage market trends

Current market developments along megatrends SCHOTT Pharma with broadest industry portfolio

Biologics Growing demand for specialized drug containment and delivery solutions, e.g. GLP-1, ADCs, mRNA

Prefillable glass and polymer syringes, ready-to-use (RTU) cartridges, specialty vials

Homecare Solutions

Higher patient comfort and reduced healthcare

costs through self-administration

Large- and small- volume prefillable glass and polymer syringes, (RTU) cartridges

Manufacturing shift

Industry-wide shift of processes to RTU,

supported by GMP Annex 1

Extensive RTU portfolio; co-founder of Alliance for RTU

Sustainability Continued, ongoing transition towards

more sustainable processes

Initiatives to de-carbonize production and value chain

Expansion of strong-margin HVS drives profitable growth

HVS' strategic importance

Strong-margin HVS drive growth and margin expansion.

Strategy focuses on addressing pharma trends with innovation.

Continuous increase of HVS revenue share reflects success.

Innovation

Pioneering new solutions along pharma trends

Introduction of first 5.5 ml prefillable staked-needle glass syringe for Ypsomed's YpsoMate® 5.5 autoinjector

Partnership with SHL Medical to launch a large-volume sterile cartridge for autoinjectors

Driving innovation to protect sensitive biologics

Launch of the first ISO-compliant RTU polymer cartridge, expanding design and device options

Introduction of SCHOTT TOPPAC® freeze polymer syringe for temperatures as low as -180 °C, used e.g. in cell and gene therapies.

Redefining safety, efficiency, and sustainability

Launch of SCHOTT TOPPAC® infuse polymer syringe system, developed with Schreiner Medipharm

Further growth of Alliance for RTU improves collaboration and production efficiency

Preparing for future growth and strengthening competitiveness

Financial Update

Reinhard Mayer, CFO

Profitable growth driven by high-value solutions

Key developments

Record revenue in FY 2025, fueled by sustained high demand for HVS.

Drug Delivery Systems (DDS) delivered resilient performance -1.3%, with strong glass syringe demand offsetting softness in polymer syringes.

Drug Containment Solutions (DCS) achieved elevated growth of +11.9% at constant currencies, propelled by strong HVS demand – especially for sterile cartridges and specialty vials.

¹ Segment split excluding consolidation effects, cc = at constant currencies

Product mix and cost benefits resulted in strong EBITDA growth

Key developments

Strong EBITDA improvement due to a product mix shift towards HVS as well as efficiency gains.

Slightly declined DDS EBITDA margin reflects ramp-up costs and lower utilization in polymer, partly compensated by strong glass syringes performance. Maintaining industry leading margin of 34.6%.

DCS delivered remarkable EBITDA growth of 34.9% at constant currencies, supported by positive product mix and operational efficiencies strongly lifting margins (+4.0pp to 23.5%).

¹ Segment split excluding consolidation effects, cc = at constant currencies

Further down the P&L…

EURm

	2025	2024	Δ yoy
EBIT	201	193	+4%
Financial result	-13	-9	-44%
EBT	188	184	+2%
Income tax expense	-41	-34	-21%
Profit for the period	147	150	-2%
EPS (EUR)	0.97	0.99	-2%
Dividend proposal (EUR)	0.18	0.16	+13%

Key developments

EBIT+4% due to higher depreciation reflecting significant investments in capacity expansion projects in recent years.

Financial result declined due to higher interest expenses.

Higher tax rate in 2025 due to global minimum tax (Pillar 2) and country mix effects.

Dividend proposal presents third consecutive increase since IPO.

Growth investments funded by positive cash flow

Free cash flow

Key developments

Higher working capital and timing of tax payments more than offset EBITDA improvement, resulting in a reduced operating cash flow.

Capital expenditure of EUR 145m at prior year's level, driven by strategic investments in capacity expansions, particularly for HVS.

¹Op. CF = Cash flow from operating activities; 2 Inv. CF = Cash flow from ongoing investing activities

FY 2026 guidance: Bridge year

	FY 2026
Revenue growth1	2% - 5%
EBITDA margin	Around 27%
Additional information	CAPEX2 of EUR 140 – 160m
	HVS revenue share on prior year´s level

Our expectation for 2026

• Growth to be entirely driven by DCS
• DDS to be impacted by the unexpected revised market outlook of a key customer resulting in lower glass syringes demand
• Profitability lower due to product mix effects, a temporary underutilization of capacities in DDS, and ramp-up costs for new factories
• Continued investments into innovation, capacity expansion, and operational excellence

¹At constant currencies; ²Capex excluding leasing

Mid-term outlook

Andreas Reisse, CEO

Updated mid-term outlook 2027-2029, strategic priorities remain unchanged

Revenue growth¹

Mid-term 2027–2029

CAGR of

6% - 8%

Increasing towards 30%

Market fundamentals are fully intact

• Increasing number of innovative therapies
• Demographic changes, rising welfare and better access to medicine

Recent challenges in market dynamics

• Dampened dynamics in vaccination and mRNA
• Geopolitical shifts

Short- and long-term drivers particularly for HVS

• Rising demand for injectables (e.g. GLP-1) with strong R&D pipeline e.g. biologics, such as ADCs and biosimilars
• Increase of therapies for subcutaneous self administration via large volume devices
• Manufacturing shift towards RTU vials and cartridges

1At constant currencies

Thank you for your attention Next financial events

Feb 11, 2026: Q1 2026 results Feb 3, 2026: AGM

May 13, 2026: Q2 2026 results

Next conference participations

Jan 13, 2026: ODDO BHF German Investment Seminar New York

Jan 19, 2026: Kepler Cheuvreux German Corporate Conference Frankfurt

Mar 3, 2026: Morgan Stanley European Healthcare Conference London

Mar 4, 2026: UBS European Healthcare Conference

London

© SCHOTT Pharma